Tolerance of Toxicities of Oral Anticancer Agents among Older Adults with Advanced Cancers
This project is focused on older adults taking oral anticancer agents, OAA. Specifically, capecitabine, an oral chemotherapy, is studied for its use in older adults with advanced cancer. Potentially, older patients may less tolerate OAA toxicities, which will impact the treatment effects and their quality of life. The overarching purpose is to explore the occurrence and effects of OAA toxicity-related symptoms in older adults taking capecitabine using real-world patient data from EHR. We will examine the potential differences in side effects of patients aged more than 65 years and patients less than 65 years from the use of capecitabine. From this data analysis, we will identify determinants through demographics, clinical characteristics, performance status, and the impact of OAA toxicity on treatment plan and performance status changes.